• PN: B113366

COMPONENTS

45x Ab-conjugated beads (S5P4 - human BlyS Ab-bead). PN: B113366A. One vial containing 100 µL of anti-human BlyS conjugated to AimPlex Bead S5P4.

25x Biotin-detection Ab (human BlyS Biotin-dAb). PN: B113366B. One vial containing 100 µL of biotinylated anti-human BlyS.

Lyophilized Standard Mix-Human Group 5 Panel A, 8-Plex. PN: HG50008. One vial containing lyophilized recombinant human sE-Cadherin, sLIGHT, sTRAIL-R3, s4-1BB, sCD30L, sVEGFR2, BLyS, and sPECAM-1.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human APRIL/TNFSF13/sCD256.  Can be multiplexed with other analytes in Human Group 5.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 5 pg/mL

Quantitation range:

LLOQ: < 10 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 5: Negligible

Sample volume: 15 µL/test

Description:

B Lymphocyte Stimulator (BLyS), also known as B-cell activating factor (BAFF), CD257 and as tumor necrosis factor ligand superfamily member 13B (TNFSF13B), is a cytokine protein. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. As an immunostimulant, BLyS is necessary for maintaining normal immunity. Inadequate level of BLyS will fail to activate B cells to produce enough immunoglobulin and will lead to immunodeficiency. Excessive level of BLyS causes abnormally high antibody production, results in systemic lupus erythmatosis, rheumatoid arthritis, and many other autoimmune diseases.  BLyS is one of the most important cytokines involves in the modulation of the immune system and is deeply connected with food and nutrition; it is also produced by cells of bowel mucosa when some foods react with the innate immunity and determine inflammation. BLyS had been first studied in patients with inflammatory bowel disease.  Moreover, in patients with celiac disease, serum BLyS levels are reduced after a gluten-free diet. Diseases associated with TNFSF13B include sialadenitis and localized scleroderma.

References:

1.      Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (Jun 1999). "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth". The Journal of Experimental Medicine 189 (11): 1747–56. doi:10.1084/jem.189.11.1747. PMC 2193079. PMID 10359578.

2.      Lied GA, Berstad A (Jan 2011). "Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review". Scandinavian Journal of Immunology 73 (1): 1–7. doi:10.1111/j.1365-3083.2010.02470.x. PMID 21128997.

3.      Piuri G, Soriano J, Speciani MC, Speciani AF (2013). "B cell activating factor (BAFF) and platelet activating factor (PAF) could both be markers of non-IgE-mediated reactions". Clinical and Translational Allergy 3 (Suppl 3): O5. doi:10.1186/2045-7022-3-S3-O5. PMC 3723786.

4.      Lied GA, Lillestøl K, Valeur J, Berstad A (Jul 2010). "Intestinal B cell-activating factor: an indicator of non-IgE-mediated hypersensitivity reactions to food?". Alimentary Pharmacology & Therapeutics 32 (1): 66–73. doi:10.1111/j.1365-2036.2010.04314.x. PMID